A Randomized, Double-blind, Placebo-Controlled, Repeat-Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of L47 in Subjects With Type 2 Diabetes Mellitus on Stable Metformin

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 12 Dec 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hepalatide (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Shanghai HEP Pharmaceutical

Most Recent Events

03 Dec 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
03 Dec 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2025.
03 Dec 2023 Status changed from not yet recruiting to withdrawn prior to enrolment as this study was not approved by CFDA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight